Univariate and multivariate analyses of variables associated with progression of fibrosis in this population are shown in Tables 2A and 2B. In univariate analysis (Table 2A), younger recipient’s age (p=0.02), higher HCV viral load four months after OLT (p=0.002), CMV infection (p<0.001), IL-2RA treatment (p<0.001), HCV antiviral therapy (p=0.017) and steroid therapy for ACR (p=0.043) were associated with higher hazards for the progression of fibrosis after OLT. This evidence concerns the gene ACR and cytomegalovirus infection.